Tavros Therapeutics is a precision oncology platform that utilizes synthetic lethality to target genetic vulnerabilities in tumors, enabling the development of small-molecule drug candidates. The company’s proprietary platform enhances drug discovery by mapping critical genetic interactions, addressing the need for more effective cancer therapies.
Funding
$17.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VTFounders
Product
Problem
Many cancers lack effective treatments due to the complex genetic interactions that drive tumor growth and resistance. Traditional drug discovery methods often fail to identify vulnerabilities specific to individual tumors, leading to limited efficacy and significant side effects. There is a need for more precise and targeted cancer therapies that exploit the unique genetic profiles of tumors.
Solution
Tavros Therapeutics is developing precision oncology therapeutics by leveraging synthetic lethality to target genetic vulnerabilities specific to tumors. The company's platform maps critical genetic interactions within tumors, enabling the discovery of novel drug targets and biomarkers. By identifying these vulnerabilities, Tavros aims to develop small-molecule drug candidates that selectively target cancer cells while minimizing harm to healthy tissue. This approach allows for the development of more effective cancer therapies with defined patient subsets.
Target Audience
Tavros Therapeutics' primary target audience includes pharmaceutical companies and oncology researchers seeking novel drug targets and biomarkers for precision cancer therapies.
Features
- Functional genomics technologies to uncover unique vulnerabilities within tumors
- Computational genomics technologies to discover novel targets and biomarkers
- Identification of novel clinical positioning strategies for existing molecules
- Synthetic vulnerability platform for genetically targeted cancer treatment
- Focus on areas of high unmet clinical need